Doximity, Inc.
Here’s whether Doximity, Inc. (DOCS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.21% over 10 days); RSI 61 — healthy momentum range; 3-month momentum positive (+27.0%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -60.5%; declining volume on rally — weak conviction (0.74x 30d avg). Currently 66.9% off its 52-week high. Score: +0/7.
DOCS is trading below its 200-day MA ($30.31) — a key warning sign the longer-term trend is under pressure. An RSI of 60.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -60.5% compares to +20.5% for SPY (trailed the market by 81.0%). The current 66.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.